Tuesday, January 21, 2020

Calidi Biotherapeutics Raises Series A Funding

San Diego-based Calidi Biotherapeutics, which is developing cell-based oncolytic virus immunotherapies for cancer, has raised a Series A funding, from two, South Korean investment companies, the company announced this morning. Size of that Series A funding was not announced. The funding came from Won & Partners and Greentable Co., Ltd. According to Calidi Biotherapeutics, the new funding will go towards advancing manufacturing for its pre-IND and IND filings. Allan Camaisa is CEO of Calidi Biotherapeutics. Calidi said the financing was arranged by Heehyoung Lee, Ph.D., co-founder and managing partner of LumeBio. Lee previously served at Hanmi Pharmaceuticals, Sorrento Therapeutics, and City of Hope, and she is now serving as an advisor to Calidi Biotherapeutics.